Could a tiny dose of a diabetes drug stop weight regain in HIV patients?
NCT ID NCT07325500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a very low dose of semaglutide (a drug used for weight loss and diabetes) can help people with HIV avoid regaining weight after an initial weight-loss period. About 30 adults with HIV who are on stable HIV treatment and are overweight or obese will take part. The goal is to see if this approach is safe and effective for long-term weight management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?